No Data
No Data
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11
BTIG analyst Thomas Shrader maintains $Acumen Pharmaceuticals(ABOS.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 37.8% and
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)
Buy Rating Justified: Acumen Pharmaceuticals' Promising Position in Alzheimer's Treatment Market
Express News | HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Acumen Pharmaceuticals' Sabirnetug: A Novel Approach in Alzheimer's Disease Treatment Warrants a Buy Rating
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
No Data